<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312413</url>
  </required_header>
  <id_info>
    <org_study_id>CYYY2017</org_study_id>
    <nct_id>NCT03312413</nct_id>
  </id_info>
  <brief_title>Efficacy of Dexmedetomidine for Cough Suppression in Patients Undergoing Thyroid Surgery</brief_title>
  <acronym>EDCSTS</acronym>
  <official_title>Efficacy of Dexmedetomidine for Cough Suppression During Anesthetic Emergence in Patients Undergoing Thyroid Surgery: A Randomized, Double Blinded, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Min Su</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maintenance of a remifentanil infusion during anesthetic emergence has been reported to
      decrease the incidence of coughing and thereby help to ensure a smooth emergence. It may,
      however, cause respiratory depression and possibly delay emergence. The purpose of this study
      was to investigate the effect of different dose of dexmedetomidine infusion on cough
      suppression during emergence from general anesthesia in patients undergoing thyroid surgery.

      American Society of Anesthesiologists physical status I-II adults undergoing elective
      thyroidectomy under general anesthesia are recruited and randomly allocated to receive
      dexmedetomidine iv infusion of 0.2μg·kg-1·h-1 (Group D1, n = 100), 0.5μg·kg-1·h-1 (Group D2,
      n = 100), 0.7μg·kg-1·h-1 (Group D3, n = 100) or saline (Group C, n = 100). Primary outcome is
      the incidence of coughing during emergence. Second outcomes include severity of coughing,
      which is assessed using a four-point scale; Ramsay score, Bruggrmann comfort scale score, VAS
      pain score are recorded. The respiratory rate (RR), heart rate (HR), and mean arterial
      pressure are also recorded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of coughing during anesthetic emergence</measure>
    <time_frame>within 10 minutes after endotracheal extubation</time_frame>
    <description>incidence of coughing within 10 minutes after extubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ccoughing on a four-point scale during anesthetic emergence</measure>
    <time_frame>within 10 minutes after endotracheal extubation</time_frame>
    <description>Evaluate the severity of coughing within 10 minutes after extubation by a four-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramsay score during anesthetic emergence</measure>
    <time_frame>within 30 minutes after endotracheal extubation</time_frame>
    <description>Ramsay score 1min, 5min, 10min, and 30min after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bruggrmann comfort scale score</measure>
    <time_frame>within 24 hrs after endotracheal extubation</time_frame>
    <description>Bruggrmann comfort scale score 30min and 24 hrs after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain score</measure>
    <time_frame>within 48 hrs after endotracheal extubation</time_frame>
    <description>VAS pain score 30min, 24 hrs and 48 hrs after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate (RR)</measure>
    <time_frame>within 30min after endotracheal extubation</time_frame>
    <description>Respiratory rate 1min, 5min, 10min, and 30min after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>within 30 minutes after endotracheal extubation</time_frame>
    <description>Heart rate 1min, 5min, 10min, and 30min after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean arterial pressure</measure>
    <time_frame>within 30 minutes after endotracheal extubation</time_frame>
    <description>Mean arterial pressure 1min, 5min, 10min, and 30min after extubation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Anesthesia Complication</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine median dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (normal saline group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride</intervention_name>
    <description>Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery</description>
    <arm_group_label>Dexmedetomidine low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery</description>
    <arm_group_label>Control group (normal saline group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride</intervention_name>
    <description>Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery</description>
    <arm_group_label>Dexmedetomidine median dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride</intervention_name>
    <description>Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery</description>
    <arm_group_label>Dexmedetomidine high dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 30Kg/m2 ≥ BMI &gt; 18Kg/m2;

          2. undergoing general anesthesia;

          3. ASA physical status I and II

          4. undergoing elective thyroid surgery.

        Exclusion Criteria:

          1. hyperthyroidism;

          2. preoperative bradycardia;

          3. liver function impairment;

          4. renal function impairment;

          5. heart function failure;

          6. history of asthma or COPD;

          7. history of diabetes;

          8. cognition function impairment;

          9. pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SU Min, M.D.</last_name>
    <phone>86-23-89011068</phone>
    <email>ms89011068@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China,Chongqing The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Min, MD</last_name>
      <phone>+86-23-89011068</phone>
      <email>ms89011068@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Min Su</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>coughing during anesthetic emergence</keyword>
  <keyword>thyroid surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

